The comparative multiple-dose intraocular pressure responses of nadolol and timolol in glaucoma and ocular hypertension.
In a double-masked clinical study the relationship between acute and chronic IOP responses to topical Nadolol 2% solution and Timolol 0.25% solution twice daily was investigated in 10 patients with glaucoma or ocular hypertension. Both drugs were evaluated in an intra-individual comparison over 4 weeks. Nine patients completed the study, one was discontinued because of essential loss of response to both drugs. At the beginning of therapy Timolol as well as Nadolol gave a mean IOP reduction of about 40% relative decrease. During the following visits the Nadolol treated eyes were significantly higher in IOP than the Timolol treated eyes. The maximum IOP effect of the first day of treatment could not be reproduced by either drug at the subsequent checks. There had been no significant changes of blood pressure, pulse rate or pupillary diameter.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005901:Glaucoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure; D008875:Middle Aged; D009248:Nadolol; D009798:Ocular Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol; D013999:Timolol